Intens Care Med:氯化物的增加与危重患儿的死亡率独立相关

2018-11-05 xing.T MedSci原创

由此可见,入院第一天血清氯化物水平的增加较为常见,并且是危重患儿死亡率的独立危险因素。需要进一步的研究来确定氯化物紊乱如何导致危重患儿的死亡风险。

近日,危重病医学领域权威杂志Intensive Care Medicine上发表了一篇研究文章,该研究的目的是确定重症儿童死亡率与入院时氯化物水平和/或氯化物水平升高之间是否存在关联。

研究人员对2014年1月至2015年12月期间入住儿科重症监护病房(PICU)的所有患者进行了一项回顾性队列研究。患者因以下原因被排除在外:(1)年龄<90天或>18岁,(2)入住心脏重症监护室,(3)入住PICU时没有实验室检查结果,(4)终末期肾病史,(5)氯化物转运障碍和(6)糖尿病酮症酸中毒入院。根据入院时氯化物水平(低氯血症<96mEq/L;正常血症为96-109mEq/L;和高氯血症≥110mEq/L)对患者进行分层,并根据住院第一天氯化物的增加水平进行分类(<5mEq/L和≥5mEq/L)。研究人员的主要结局是院内死亡率。

该研究共纳入了1935名患者[55%为女性,中位年龄为6.3岁,IQR为(1.9-13.4)]。总死亡率为4%(n=71),第2天AKI发生率为17%(n=333)。低氯血症、高氯血症和血清氯化物增加≥5mEq/L的发生率分别为2%、21%和12%,调整混杂因素后,氯化物增加≥5mEq/L与死亡率增加2.3(95%CI为1.03-5.21)相关。

由此可见,入院第一天血清氯化物水平的增加较为常见,并且是危重患儿死亡率的独立危险因素。需要进一步的研究来确定氯化物紊乱如何导致危重患儿的死亡风险。

原始出处:

Matthew F. Barhight, et al. Increase in chloride from baseline is independently associated with mortality in critically ill children.Intensive Care Medicine.2018. http://icmjournal.esicm.org/journals/abstract.html?v=0&j=134&i=0&a=5424_10.1007_s00134-018-5424-1&doi=

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038986, encodeId=1979203898632, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 27 22:27:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517668, encodeId=1ee0151e66820, content=<a href='/topic/show?id=a8416408096' target=_blank style='color:#2F92EE;'>#氯化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64080, encryptionId=a8416408096, topicName=氯化物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c0011104054, createdName=ms1260584454294838, createdTime=Wed Nov 07 05:27:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609294, encodeId=01cf1609294dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 07 05:27:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038986, encodeId=1979203898632, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 27 22:27:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517668, encodeId=1ee0151e66820, content=<a href='/topic/show?id=a8416408096' target=_blank style='color:#2F92EE;'>#氯化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64080, encryptionId=a8416408096, topicName=氯化物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c0011104054, createdName=ms1260584454294838, createdTime=Wed Nov 07 05:27:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609294, encodeId=01cf1609294dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 07 05:27:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038986, encodeId=1979203898632, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Tue Nov 27 22:27:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517668, encodeId=1ee0151e66820, content=<a href='/topic/show?id=a8416408096' target=_blank style='color:#2F92EE;'>#氯化物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64080, encryptionId=a8416408096, topicName=氯化物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c0011104054, createdName=ms1260584454294838, createdTime=Wed Nov 07 05:27:00 CST 2018, time=2018-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609294, encodeId=01cf1609294dc, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 07 05:27:00 CST 2018, time=2018-11-07, status=1, ipAttribution=)]

相关资讯

JAMA:ICU患者限制静脉注射液中氯化物可降低AKI发生率

  澳大利亚、马来西亚联合进行的研究显示,对重症监护病房(ICU)患者限制静脉输注液中的氯化物浓度,可显著降低其急性肾损伤(AKI)发生率和肾脏替代治疗(RRT)使用率。论文发表于10月17日出版的《美国医学会杂志》[JAMA 2012,308(15):1566]。   该研究分为对照期(2008年2月18日-8月17日,n=760)、洗脱期和干预期(2009年同期,n=773)。对照